Recent advances in the ability to deliver boron-containing drugs to brain tumors have generated interest in -4 MeV linacs as sources of epithermal neutrons for radiation therapy. In addition, fast neutron therapy facilities have been studying methods to moderate their beams to take advantage of the high cross section for epithermal neutrons on boron-10. This paper describes the technical issues involved in each approach and presents the motivation for undertaking such studies using the Fermilab linac. The problems which must be solved before therapy can begin are outlined. Status of preparatory work and results of preliminary measurements are presented.
I. INTRODUCTION
Despite the efforts of many researchers, the prognosis for a patient diagnosed with an inoperable advanced brain tumor (glioma) is dismal. The difficulty with using radiation therapy is that the tumor propagates by sending out microscopic clusters of cells close to the main body of the tumor. Even when the gross tumor is killed by radiation these clusters continue to grow. If a large margin is included around the gross tumor it is possible to destroy the clusters, but the process causes unacceptable damage to the healthy tissue in which the clusters are embedded. Hence, it is advantageous to sensitize the tumor cells to radiation without sensitizing the healthy cells. One way to sensitize the tumor is to introduce into the body a compound containing boron-10. Depending on the exact nature of the carrier, boron-10 will be absorbed by various parts of the body, including the tumor. However, healthy brain tissue will not absorb the compound because it is protected by the blood-brain barrier. When the brain is exposed to neutron radiation the large cross section for interactions between thermal neutrons and boron-10 will result in a larger dose to tumor than healthy tissue. This form of radiation therapy is called boron neutron capture therapy
In recent years the Department of Energy has been supporting research in the development of boron pharmaceuticals, and a number of drugs are ready or nearly ready for clinical trials. In addition, several reactors have been modified to provide neutrons for early clinical trials [l] and work is proceeding on a tandem cascade accelerator [2] . However, much remains to be done in developing accelerator sources needed to make BNCT more widely available. Because of the high currents needed to achieve adequate dose rates, proton linacs are well suited for this application. 
II. PRODUCTION NEAR THRESHOLD
The present consensus is that the optimum neutron energy for BNCT is in tens of keV. In this energy range neutrons will penetrate the skull and be thermalized by the time they reach the tumor. One approach is to produce neutrons at an energy as close as possible to the keV range in order to minimize the need for moderating material. Recent progress in the technology of radiofrequency quadrupole (RFQ) linacs and the 1.8 MeV production threshold for the 7Li(p,n)7Be reaction have led to the hope that a 2.5 MeV RFQ could accelerate protons which would strike a lithium target to produce the neutrons [3] . Despite a great deal of interest in this approach, the critical problems remain unsolved. Estimates of the average proton current required for acceptable dose rates range from 5 to 30 milliamperes [21,[41. This uncertainty is largely due to uncertainties in the relative biological effectiveness (RBE) of neutrons in tissue at these energies. Current requirements decrease with increasing RBE, but until at least one prototype is constructed the RBE's cannot be measured. In addition, a moderating system must be incorporated to accommodate the fact that the neutrons produced in this reaction are too energetic. A number of moderating schemes have been proposed but they cannot be evaluated until an accelerator becomes available. Finally, the problem of cooling the lithium target is unlikely to be solved within reasonable economic constraints, and the safety issues related to using lithium in a clinical environment are formidable.
The difficulties associated with a lithium target have led to interest in using a beryllium target. Beryllium has a higher melting point than lithium, is easier to cool, and has been used successfully in clinical fast neutron therapy facilities. The neutron production threshold for protons impinging on a beryllium target is 2.2 MeV and the yield becomes comparable to a lithium target yield at about 4 MeV. Using 4 MeV protons and a beryllium target produces even more energetic neutrons than the system described above. Monte Carlo studies indicate that the spectrum can be moderated to reduce the high energy component [5] but no work is being done on designing a 4 MeV proton source for BNCT. It is believed that a 4 MeV RFQ is impractical and that a drift tube linac (DTL) is required. Use of a DTL with a beryllium target will solve the technical issues associated with the target but the questions relating to specifying an appropriate proton current remain unanswered. The most economical approach is to identify an existing 4 MeV accelerator and use it and a prototype moderating system to measure RBE's and dose rates. Such experiments would provide the data needed to extrapolate to the DTL operating parameters with confidence. This step is critical for the continued evolution of compact neutron sources for BNCI'. 
IU. SPALLATION SOURCES

V. CONCLUSIONS
Present schemes for accelerator-produced neutron beams for BNCT use trixie-offs between lower yield reactions with neutron energies as close as possible to epithermal energies and higher yield "ions with higher energy neutrons. h t o n linacs play an importaut role in both scenarios. However, before linacs can be used for BNCT a great deal of work must be done. In some cases it would be good to use data from existfng lower current accelerators to obtain the information needed to design practical systems. 
VI. REFERENCES
[
